Company profile
Galmed Pharmaceuticals Ltd.
NASDAQ:GLMDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Aramchol meglumine | phase2 | — | 2 | completed, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04104321 | phase3 | suspended | 2019-09-23 | 2022-12-08 | Galmed Research and Development, Ltd. | A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) |
| NCT02279524 | phase2 | completed | 2015-04-29 | 2018-05-22 | Galmed Research and Development, Ltd. | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH |
| NCT05857215 | phase1 | completed | 2021-03-05 | 2021-07-01 | Galmed Pharmaceuticals Ltd | A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects |
| NCT00776841 | phase1 | completed | 2008-09-01 | 2009-09-01 | Galmed Medical Reserch | A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers |
| NCT06095986 | phase2 | withdrawn | 2025-06-01 | 2026-09-01 | Galmed Pharmaceuticals Ltd | A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis |
FDA applications (0)
No records yet.